证券代码：605008 证券简称：长鸿高科 公告编号：2025-042 宁波长鸿高分子科技股份有限公司 第三届监事会第十四次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 宁波长鸿高分子科技股份有限公司（以下简称"公司"或"上市公司"）第 三届监事会第十四次会议（以下简称"本次会议"）于 2025 年 7 月 17 日在公司 会议室以现场结合通讯方式召开，本次会议通知已于 2025 年 7 月 15 日通过电子 邮件的方式送达公司全体监事，本次会议为紧急会议，全体监事一致同意豁免本 次会议的通知时限。本次会议由监事会主席仲章明先生主持，会议应参加表决监 事 3 人，实际参加表决监事 3 人。本次会议的召集、召开符合《中华人民共和国 公司法》等法律、法规和《宁波长鸿高分子科技股份有限公司章程》（以下简称 "《公司章程》"）的有关规定。 二、监事会会议审议情况 经与会监事审议，做出以下决议： （一）审议通过《关于公司符合发行股份、可转换公司债券及支付现金购 买资产并募集配套资金条件的议案》 ...

公司拟通过发行股份、可转换公司债券及支付现金的方式，购买海南定恒创 业投资有限公司、宁波定科企业管理合伙企业（有限合伙）、宁波定高新材料有 限公司（以下合称"交易对方"）合计持有的广西长科新材料有限公司（以下简 称"广西长科"或"标的公司"）100%股权（以下简称"本次发行股份、可转换 公司债券及支付现金购买资产"或"本次重组"，其中标的公司 100%股权简称"标 的资产"），并募集配套资金（以下简称"本次募集配套资金"，与本次重组合称 "本次交易"）。 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司重大资 产重组管理办法》《上市公司证券发行注册管理办法》《上市公司向特定对象发行 证券代码：605008 证券简称：长鸿高科 公告编号：2025-041 宁波长鸿高分子科技股份有限公司 第三届董事会第十九次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 宁波长鸿高分子科技股份有限公司（以下简称"公司"或"上市公司"）第 三届董事会第十九次会议于 2025 年 7 月 17 日在 ...

宁波长鸿高分子科技股份有限公司 第三届董事会独立董事专门会议第八次会议决议 宁波长鸿高分子科技股份有限公司第三届董事会独立董事专门会议第八次 会议于2025年7月17日下午14:00在公司会议室以现场结合通讯会议方式召开。 会议应到独立董事 3 人，实际出席 3 人。本次会议的召集和召开程序符合《中 华人民共和国公司法》和《公司章程》《独立董事工作制度》的有关规定。经与 会独立董事逐项审议，一致通过以下决议： 一、审议通过《关于公司符合发行股份、可转换公司债券及支付现金购买 资产并募集配套资金条件的议案》 表决结果：3 票赞成、0 票反对、0 票弃权。 二、逐项审议通过《关于公司发行股份、可转换公司债券及支付现金购买 资产并募集配套资金暨关联交易方案的议案》 （一）本次交易总体方案 表决结果：3 票赞成、0 票反对、0 票弃权。 （二）发行股份情况 1、发行股份的种类和面值 表决结果：3 票赞成、0 票反对、0 票弃权。 2、发行股份的定价依据、定价基准日和发行价格 表决结果：3 票赞成、0 票反对、0 票弃权。 （三）发行可转换公司债券情况 3、发行对象 表决结果：3 票赞成、0 票反对、0 票弃权。 4、 ...

长鸿高科：拟购买广西长科100%股权 股票将于7月21日复牌 智通财经7月18日电，长鸿高科(605008.SH)公告称，公司拟通过发行股份、可转换公司债券及支付现金 方式，购买广西长科新材料有限公司100%股权，并向不超过35名特定投资者发行股份募集配套资金。 经向上海证券交易所申请，公司股票将于2025年7月21日（星期一）开市起复牌。 ...

Core Viewpoint - Ningbo Changhong High Polymer Technology Co., Ltd. (Changhong High Tech) expects a significant decline in net profit for the first half of 2025, projecting a profit of 4 million to 6 million yuan, representing a year-on-year decrease of 93.79% to 95.86% due to production disruptions and market demand issues [1][2] Group 1: Financial Performance - The company anticipates a net profit of 4 million to 6 million yuan for the first half of 2025, a decrease of 93.79% to 95.86% compared to the previous year [1] - The decline in performance is attributed to a prolonged shutdown for technical upgrades at its subsidiary, Zhejiang Changhong Biomaterials Co., Ltd., which affected production capacity [1] - Market demand has been insufficient, leading to a larger drop in product sales prices compared to raw material prices, resulting in a decline in gross margin [1] Group 2: Strategic Outlook - Changhong High Tech has established a dual-driven development pattern in the thermoplastic elastomer (TPES) and biodegradable PBAT sectors, focusing on a comprehensive industrial layout for biodegradable plastics [1] - The management emphasizes that the technical upgrades, while impacting short-term profits, will support cost reduction and market expansion in the future [1] - With the implementation of national policies aimed at boosting domestic demand and consumption, the overall industry outlook is improving, and the company's product market is expected to gradually recover [1][2] Group 3: Future Growth Potential - Following the completion of technical upgrades and stabilization of production, Changhong High Tech achieved better profitability in the second quarter, indicating positive signals for recovery [2] - The company aims to restore growth momentum in the second half of the year through technological upgrades, capacity optimization, and market expansion [2] - Changhong High Tech is focused on consolidating its leading position in the industry and injecting new momentum for long-term high-quality development [2]

证券代码：605008 证券简称：长鸿高科 公告编号：2025-040 根据上海证券交易所的相关规定，经公司申请，公司股票（证券简称：长鸿 高科，证券代码：605008）自 2025 年 7 月 8 日（星期二）开市起停牌，预计停 牌时间不超过 10 个交易日。详情请参见公司于 2025 年 7 月 8 日在上海证券交易 所网站（www.sse.com.cn）及指定媒体披露的《宁波长鸿高分子科技股份有限公 司关于筹划重大资产重组的停牌公告》（公告编号：2025-037）。 截至本公告披露日，公司及有关各方正积极推进本次交易的相关工作。为维 护投资者利益，避免公司股价异常波动，根据上海证券交易所的相关规定，公司 股票继续停牌。停牌期间，公司将严格按照相关法律法规、规范性文件的有关规 定推进本次交易事项的各项工作，并根据本次交易进展情况，履行信息披露义务， 待相关事项确定后，公司将及时发布相关公告并申请公司股票复牌。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 宁波长鸿高分子科技股份有限公司董事会 宁波长鸿高分子科技股份有限公 ...

重要内容提示： （一）业绩预告期间 （二）业绩预告情况 利润 400.00 万元到 600.00 万元，与上年同期（法定披露数据）相比，将减少 -300.00 万元到-150.00 万元，与上年同期（法定披露数据）相比，将减少 7,215.65 万元到 7,365.65 万元，同比减少 102.12%到 104.25%。 证券代码：605008 证券简称：长鸿高科 公告编号：2025-039 宁波长鸿高分子科技股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 二、上年同期业绩情况 （一）利润总额：10,558.73 万元。归属于上市公司股东的净利润：9,657.09 万元。归属于上市公司股东的扣除非经常性损益的净利润：7,065.65 万元。 （二）基本每股收益：0.15 元。 三、本期业绩预减的主要原因 公司 2025 年 1-6 月业绩预减主要是公司子公司浙江长鸿生物材料有限公司 为了提升现有装置的生产效率，在 2025 年第一季度进行了 PBT 装置技改，技改 停工时间较长影响了产量；同时，由于市场需求阶段性 ...

宁波长鸿高分子科技股份有限公司（以下简称"公司"）正在筹划以发行股 份、可转换公司债券及支付现金的方式购买广西长科新材料有限公司 100%股权 并同时募集配套资金（以下简称"本次交易"）。 证券代码：605008 证券简称：长鸿高科 公告编号：2025-040 宁波长鸿高分子科技股份有限公司 根据上海证券交易所的相关规定，经公司申请，公司股票（证券简称：长鸿 高科，证券代码：605008）自 2025 年 7 月 8 日（星期二）开市起停牌，预计停 牌时间不超过 10 个交易日。详情请参见公司于 2025 年 7 月 8 日在上海证券交易 所网站（www.sse.com.cn）及指定媒体披露的《宁波长鸿高分子科技股份有限公 司关于筹划重大资产重组的停牌公告》（公告编号：2025-037）。 截至本公告披露日，公司及有关各方正积极推进本次交易的相关工作。为维 护投资者利益，避免公司股价异常波动，根据上海证券交易所的相关规定，公司 股票继续停牌。停牌期间，公司将严格按照相关法律法规、规范性文件的有关规 定推进本次交易事项的各项工作，并根据本次交易进展情况，履行信息披露义务， 待相关事项确定后，公司将及时发布相关公 ...

[Half-Year Performance Forecast](index=1&type=section&id=I.%20Half-Year%20Performance%20Forecast) The company projects a significant decline in its 2025 first-half performance, with net profit attributable to shareholders decreasing sharply and non-recurring net profit turning to a loss - The performance forecast period is from January 1, 2025, to June 30, 2025[3](index=3&type=chunk) 2025 Half-Year Performance Forecast | Indicator | Estimated Amount (RMB in millions) | Compared to Prior Year Period (RMB in millions) | Year-over-Year Change | | :--- | :--- | :--- | :--- | | **Net Profit Attributable to Shareholders** | 4.00 to 6.00 | Decrease by 90.57 to 92.57 | -93.79% to -95.86% | | **Net Profit After Non-Recurring Gains/Losses** | -3.00 to -1.50 | Decrease by 72.16 to 73.66 | -102.12% to -104.25% | [Prior Year Period Performance](index=1&type=section&id=II.%20Prior%20Year%20Period%20Performance%20Situation) In the prior year period (2024), the company achieved profitability, with net profit attributable to shareholders at RMB 96.57 million and net profit after non-recurring gains and losses at RMB 70.66 million 2024 Half-Year Performance Review | Indicator | Amount (RMB in millions) | | :--- | :--- | | Total Profit | 105.59 | | Net Profit Attributable to Shareholders | 96.57 | | Net Profit After Non-Recurring Gains/Losses | 70.66 | | Basic Earnings Per Share (RMB) | 0.15 | [Main Reasons for Performance Decline Forecast](index=2&type=section&id=III.%20Main%20Reasons%20for%20Current%20Period%20Performance%20Decline%20Forecast) The performance decline is primarily due to prolonged production halts from a subsidiary's PBT equipment upgrade and reduced gross margins caused by product price drops exceeding raw material cost reductions amid insufficient market demand; however, the company notes stabilized production and market recovery in Q2, leading to improved profitability - Subsidiary Zhejiang Changhong Biomaterials Co., Ltd. underwent a PBT equipment upgrade in Q1 2025, with prolonged downtime impacting production volume[8](index=8&type=chunk) - Gross margin declined due to product selling price reductions exceeding raw material cost decreases, driven by temporary insufficient market demand[8](index=8&type=chunk) - Production gradually stabilized and market trends showed recovery from Q2 onwards, leading to improved overall company profitability in the second quarter[8](index=8&type=chunk) [Risk Warning](index=2&type=section&id=IV.%20Risk%20Warning) The company explicitly states that this performance forecast is based on preliminary, unaudited data from its finance department, with no material uncertainties believed to affect its accuracy - This performance forecast has not been audited by a certified public accountant[9](index=9&type=chunk) - The data is based on the professional judgment of the company's finance department, with no material uncertainties believed to affect the forecast's accuracy[9](index=9&type=chunk) [Other Explanations](index=2&type=section&id=V.%20Other%20Explanations) The company advises investors that the disclosed data is preliminary, with final accurate financial figures to be officially released in the 2025 half-year report, urging caution regarding investment risks - The forecast data is preliminary, and the final accurate figures will be subject to the company's officially disclosed 2025 half-year report[10](index=10&type=chunk) - Investors are advised to be aware of investment risks[10](index=10&type=chunk)

Summary of Key Points Core Insights - The report highlights the listing and trading activities of various ETFs and bonds on July 10, 2025, indicating a busy market day with multiple announcements regarding suspensions and resumption of trading for various financial instruments [1][2][3][4][5][6][7][8][9]. Group 1: Listings and Trading Activities - The report mentions the listing of 127110 Guanghe Convertible Bond and 301603 Qiaofeng Intelligent on July 10, 2025, marking significant events for these financial instruments [1]. - Several ETFs, including 159209 China Merchants CSI All-Share Dividend Quality ETF and 159232 Southern CSI All-Share Free Cash Flow ETF, announced dividend distributions and were temporarily suspended from trading during specific hours on the same day [1]. - The report notes that multiple ETFs, such as 159351 Jiashi CSI A500 ETF and 159355 Huabao CSI 800 Dividend Low Volatility ETF, also experienced similar trading suspensions due to dividend announcements [1]. Group 2: Special Suspensions - The report details the special suspension of stock 000545 Jinpu Titanium Industry due to significant asset restructuring and related transactions, effective from July 1, 2025 [2]. - Other financial instruments, including various SCPs from Zhonglin Group, have been suspended since November 21, 2023, indicating ongoing issues or restructuring within those entities [2][3][4][5][6][7][8][9]. Group 3: General Market Activity - The report reflects a general trend of increased market activity with multiple announcements of trading suspensions and resumption, indicating a dynamic environment for investors [1][2][3][4][5][6][7][8][9]. - The focus on dividend announcements and asset restructuring suggests a strategic shift among companies to enhance shareholder value and manage financial health [1][2][3][4][5][6][7][8][9].